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Introduction 
 Some mushrooms are known to have strong antioxidant 
capacity [1]. There is an accepted relationship between the 
physiopathology of several chronic diseases and oxidative 
stress. Therefore, the use of foods such as those mushrooms 
with antioxidant capacity, as phytochemical protectors, may 
be relevant for the prevention of oxidative stress related 
diseases such as cancer. Additionally, mushrooms have been 
described as a source of potential antitumour molecules, 
making them attractive candidates for drug discovery [2,3]. 
However, there are no such studies on the Portuguese wild 
mushroom Clitocybe alexandri .  
Materials and methods 
Clitocybe alexandri (Scop.: Fr.) Pat. (Tricholomataceae) was 
collected in Bragança (Northeast Portugal), in autumn 2008. 
Taxonomic identification was made according to different 
authors and representative voucher specimens were 
deposited at the herbarium of Escola Superior Agrária of 
Instituto Politécnico de Bragança. This is a saprotrophic and 
edible species. The samples were lyophilised and reduced to 
a fine dried powder.  
The extracts studied were methanolic, ethanolic and 
polissacharidic.   
For the antioxidant activity the following assays were used: 
evaluation of DPPH (2,2-diphenyl-1-picrylhydrazyl) radical 
scavenging capacity, reducing power and inhibition of lipid 
peroxidation (LPO) measured in liposome solutions [4].  
For the analysis of extract-induced cell growth inhibition the 
SRB (sulforhodamine B) assay [5] was used, following 
treatment of four tumour cell lines (lung, breast, colon and 
gastric cancer) with the different extracts. 
 
The polysaccharidic extract presented the strongest 
antioxidant capacity (EC50 < 2.5 ± 0.0 mg/ml). Regarding the 
capacity to inhibit the growth of human tumour cell lines, 
the Ethanolic extract was the most effective, presenting the 
lowest GI50 values (GI50 < 17.95 ± 1.3 µg/ml).  
Results and discussion 
 Extracts   (%) 
Phenolics 
(mg GAE/g) 
DPPH scav. 
activity 
Reducing power 
LPO 
inhibition 
 Methanolic 47.7 ± 5.3 a 1.5 ± 0.1 a 28.7 ± 3.2 a 7.0 ± 0.4 a 4.5 ± 0.2a 
 Ethanolic 3.5 ± 0.2 6.3 ± 0.4 10.7 ± 0.8 2.3 ± 0.0 3.7 ± 0.1   
 Polysaccharidic 30.3 ± 2.8 - 2.5 ± 0.0 0.9 ± 0.0 1.2 ± 0.0 
Table 1. Antioxidant activity of Clitocybe alexandri extracts.  
Results are expressed as EC50 (concentrations of extract in mg/ml that cause 50% of antioxidant activity, unless for reducing power that is 0.5 of 
absorbance), and show means  SEM of 3 independent observations.   
  Extracts 
NCI-H460 
 (lung cancer) 
MCF-7 
(breast cancer) 
HCT-15 
 (colon cancer) 
AGS 
(gastric cancer) 
  
 Methanolic 34.85 ± 2.8 34.2 ± 1.4 36.9 ± 3.1 36.1 ± 2.3   
 Ethanolic 24.8  2.3 17.95  1.3 21.7  2.3 26.05  1.3 
 Polysaccharidic 24.55  1.8 46.8  1.6 59.1  0.7 51.75  0.9 
Table 2. Effects of Clitocybe alexandri extracts on the growth of human tumour cell lines.  
Results are expressed as GI50 (concentrations of extract in µg/ml that cause 50% of growth inhibition of human tumour cell lines), and show 
means  SEM of 3-6 independent observations performed in duplicate.g 
In summary, polysaccharidic extract of Clitocybe alexandri was 
the most potent as antioxidant, while the ethanolic extract 
was the most potent as inhibitor of growth of human 
tumour cell lines. This interesting growth inhibitory activity 
proves that this mushroom, particularly the ethanolic extract 
is a promising source of bioactive compounds. As far as we 
know, there are no reports of growth inhibitory activity of 
the studied species against lung, colon and gastric human 
cancer cells. Future work will elucidate the mechanism of 
action of these extracts leading to the observed cell growth 
inhibition. 
Conclusions 
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Objective 
The aim of the present work was to study extracts obtained 
from the wild mushroom Clitocybe alexandri for the in vitro 
antioxidant activity and growth inhibitory activity in human 
tumour cell lines.  
 
